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Abstract
Dysregulated cell–cell adhesion plays a critical role in epithelial cancer development. Studies of human and mouse cancers
have indicated that loss of adhesion complexes known as adherens junctions contributes to tumor progression and
metastasis. In contrast, little is known regarding the role of the related cell–cell adhesion junction, the desmosome, during
cancer development. Studies analyzing expression of desmosome components during human cancer progression have
yielded conflicting results, and therefore genetic studies using knockout mice to examine the functional consequence of
desmosome inactivation for tumorigenesis are essential for elucidating the role of desmosomes in cancer development.
Here, we investigate the consequences of desmosome loss for carcinogenesis by analyzing conditional knockout mice
lacking Perp, a p53/p63 regulated gene that encodes an important component of desmosomes. Analysis of Perp-deficient
mice in a UVB-induced squamous cell skin carcinoma model reveals that Perp ablation promotes both tumor initiation and
progression. Tumor development is associated with inactivation of both of Perp’s known functions, in apoptosis and cell–
cell adhesion. Interestingly, Perp-deficient tumors exhibit widespread downregulation of desmosomal constituents while
adherens junctions remain intact, suggesting that desmosome loss is a specific event important for tumorigenesis rather
than a reflection of a general change in differentiation status. Similarly, human squamous cell carcinomas display loss of
PERP expression with retention of adherens junctions components, indicating that this is a relevant stage of human cancer
development. Using gene expression profiling, we show further that Perp loss induces a set of inflammation-related genes
that could stimulate tumorigenesis. Together, these studies suggest that Perp-deficiency promotes cancer by enhancing cell
survival, desmosome loss, and inflammation, and they highlight a fundamental role for Perp and desmosomes in tumor
suppression. An understanding of the factors affecting cancer progression is important for ultimately improving the
diagnosis, prognostication, and treatment of cancer.
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Introduction
Carcinomas, or cancers of epithelia, comprise approximately
90% of all human cancers [1]. Cancers of the stratified epithelia,
such as the skin and the tissues of the head and neck, are common
and can display poor prognosis in advanced stages [2,3].
Elaborating the normal architecture and homeostatic mechanisms
of stratified epithelia, and how these are perturbed in cancer
progression and metastasis, can provide significant insight into
carcinoma development.
The genesis and maintenance of stratified epithelia, such as the
epidermis, requires the coordinated regulation of proliferation,
adhesion, migration, and differentiation [4]. Progenitor cells of the
basal, inner layer of the epidermis renew the epidermis by initially
proliferating, then exiting the cell cycle, detaching from the
basement membrane, migrating, and differentiating to form the
upper layers of the skin. The cells of stratified epithelia require a
great deal of plasticity to permit division and migration of cells
during the differentiation process while still providing a protective
barrier to prevent dehydration and infection. This plasticity relies
on the modulation of various intercellular adhesion junctions,
including tight junctions, adherens junctions and desmosomes [5].
While adherens junctions generally help to maintain cell-cell
adhesion in epithelial tissues, desmosomes have been found to be
particularly important for endowing epithelia with the strength
needed to withstand mechanical stress, via anchorage to the
intermediate filament network [5,6]. The crucial nature of
desmosomes in maintaining the integrity of stratified epithelia is
underscored by the observation that mutation or inactivation of
several desmosomal proteins is linked to human epithelial diseases
[7].
The importance of dysregulated adhesion in cancer has been
best understood from analysis of adherens junctions. Adherens
junctions promote intercellular adhesion through homotypic
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interactions between transmembrane E-cadherin molecules at the
plasma membrane [8,9] and connections to the actin cytoskeleton
via alpha-catenin and beta-catenin [10,11]. In human cancers,
inactivation of E-cadherin, through mutation, promoter methyl-
ation, or transcriptional repression, is associated with epithelial to
mesenchymal transition (EMT), progression from adenoma to
carcinoma, and the acquisition of metastatic potential [12–16].
The importance of this inactivation is underscored by functional
studies in mouse models showing that inhibition of E-cadherin in
certain tumor-prone strains facilitates invasion and metastasis [17].
In addition, compound mutant mice lacking both E-cadherin and
p53 in the mammary epithelium exhibit accelerated tumor
development and increased metastasis relative to mice lacking
only p53 [18]. Loss of p120-catenin, a key regulator of E-cadherin
stability, also promotes neoplasia, in the salivary gland and the skin
[19–21]. Similarly, specific deletion of Alpha-catenin in the mouse
epidermis results in squamous cell carcinoma development
[21,22].
While a variety of studies have implicated inactivation of
adherens junctions in tumor development and progression, the
contribution of desmosome loss to carcinogenesis remains largely
unexplored. Desmosome complexes form when the desmosomal
cadherins, desmogleins and desmocollins, participate in hetero-
typic interactions that bring the plasma membranes of adjacent
cells in close apposition [23–25]. The cytoplasmic tails of these
cadherins interact with plakoglobin [26,27] and plakophilins [28–
30], which connect to the intermediate filament cytoskeleton via
desmoplakin [31–33]. An impediment to studying desmosomes in
a genetic cancer model has been the high frequency of embryonic
or perinatal lethality observed in various knockout mice lacking
desmosomal components, precluding long-term tumor studies
[34]. Additionally, correlative studies examining expression
patterns of desmosomal components during human cancer
progression have yielded conflicting results. Several studies have
suggested that downregulation of desmosome components,
including desmoglein 3, desmoglein 2, plakoglobin, and desmo-
plakin, occurs during the progression of a variety of cancers in
humans and is often correlated with and predictive of tumor
metastasis [35–38]. In contrast, other studies have documented the
overexpression of desmosome components during the progression
of diverse cancers, and this pattern is associated with poor
prognosis [39–41]. The use of tractable genetic systems is therefore
critical for unraveling the contribution of desmosomes to cancer
development.
The Perp tetraspan membrane protein was originally identified as
a transcriptional target of the p53 tumor suppressor upregulated
during apoptosis [42]. Subsequent analysis of Perp knockout mice
revealed an additional function for Perp as a target of the p53-related
transcription factor, p63, involved in maintaining epithelial integ-
rity by promoting desmosomal cell-cell adhesion [43]. Perp2/2
mice display postnatal lethality accompanied by dramatic blisters
throughout their stratified epithelia, including the oral mucosa and
skin. Electron microscopy and biochemical analyses established that
the blistering phenotype observed in the Perp-deficient epithelia
is accounted for by both a reduction in desmosome number and
compromised desmosome complex formation. Immunogold elec-
tron microscopy demonstrating localization of Perp to desmosomes
conclusively established a clear role for Perp as a novel critical
component of the desmosome in the skin and other stratified
epithelia.
Here, we aim to characterize the consequence of Perp-deficiency
for UVB-induced squamous cell carcinoma (SCC) development in
the skin, where Perp plays a pivotal role in cell-cell adhesion and
tissue homeostasis. Using conditional Perp knockout mice to
selectively ablate Perp expression in stratified epithelia, we reveal
an important role for Perp as a tumor suppressor in this model for
human skin cancer. These results provide definitive genetic
evidence that loss of a desmosome component can in fact promote
tumorigenesis in vivo, thereby enhancing our understanding of the
factors driving tumor progression.
Results
Loss of Perp promotes tumorigenesis
To characterize the function of Perp during tumorigenesis, we
examined its role in cancer of the epidermis, where it is critical for
tissue integrity and homeostasis through its role in desmosomal
cell-cell adhesion [43]. We examined the tumor predisposition of
Perp-deficient mice using a well-defined model for squamous cell
carcinoma (SCC) development in which mice are exposed to
chronic UVB irradiation [44]. This model provides an accurate
mimic of human SCC development, which is similarly driven by
UVB irradiation. As Perp constitutive null mice die postnatally, we
utilized conditional Perp knockout mice (Perpfl/fl; fl = floxed)
expressing a tamoxifen-inducible K14CreER transgene to drive
tissue-specific deletion of the Perp locus in the epidermis [45,46].
Immunofluorescence confirmed that Perp expression was success-
fully ablated in the epidermis of the majority of these mice 4 weeks
after tamoxifen injection (Figure 1A). To induce SCC develop-
ment, tamoxifen-treated 10-week old control and Perpfl/fl mice
expressing a K14CreER transgene were exposed to chronic
treatments (2.5 kJ/m2) of UVB irradiation three times weekly for
30 weeks (Figure 1B). Interestingly, Kaplan-Meier analysis
revealed that mice lacking Perp in the epidermis developed SCCs
with reduced average latency (32 wks) compared to control mice
(51 wks; Figure 1C). In addition, the average number of SCCs per
K14CreER;Perpfl/fl mouse was far greater than in control animals
(Figure 1D). The prominent early tumor development and
increased tumor number in Perp-deficient mice compared to
controls suggest that Perp loss promotes tumor initiation.
Histological analyses to grade the SCCs according to cellular
morphology, invasiveness into the dermis, and overall architecture
revealed that SCCs arising in K14CreER;Perpfl/fl mice had a greater
Author Summary
Changes in tissue architecture, such as loss of adhesion
between cells, have been shown to facilitate cancer
development, especially metastasis where cells can detach
from a tumor and spread throughout the body. While
various studies have demonstrated that inactivation of an
adhesion complex known as the adherens junction
promotes cancer development and metastasis, little is
known about the role of the desmosome—a related cell–
cell adhesion complex—in tumorigenesis. Here we exam-
ine the consequence of desmosome-deficiency for tumor
development by studying mice lacking a key component
of desmosomes in the skin, a protein known as Perp. Using
a mouse model for human skin cancer, in which ultraviolet
light promotes skin cancer development, we demonstrate
that Perp-deficiency indeed leads to accelerated skin
tumorigenesis. We similarly observe that PERP is lost
during human skin cancer development, suggesting that
PERP is also important as a tumor suppressor in humans.
These findings demonstrate that desmosome-deficiency
achieved by Perp inactivation can promote cancer and
suggest the potential utility of monitoring PERP status for
staging, prognostication, or treatment of human cancers.
Perp and Skin Cancer
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Figure 1. Perp-deficiency promotes tumorigenesis. A) Perp immunofluorescence images demonstrating the presence of Perp in the epidermis
of control mice and the loss of Perp in the epidermis of K14CreER;Perpfl/fl mice. Green signal represents Perp staining, red signal represents staining for
the desmosomal protein Desmoplakin (Dp), and blue signal represents DAPI, to mark nuclei. (Upper left) Low magnification images show an overview
of the epidermis, and (Upper right) high magnification images show the punctate staining pattern typical of desmosomal proteins. (Lower panel)
Perp and Skin Cancer
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propensity to progress to a poorly differentiated stage than tumors
arising in control mice, suggesting that Perp loss may also
contribute to tumor progression (Figure 1E, 1F). Despite the
presence of invasive tumors, however, no metastases were
apparent in the liver or lungs of mice from either cohort (data
not shown). Together, these findings indicate that Perp is a key
suppressor of skin carcinogenesis and provide the first in vivo
demonstration that genetic loss of a desmosomal component can
lead to accelerated carcinoma development, facilitating both
tumor initiation and progression.
Perp is an important mediator of UVB-induced apoptosis
To understand the basis for the tumor development driven by
Perp-deficiency, we sought first to determine whether Perp is an
important mediator of p53-induced apoptosis in the skin in
response to ultraviolet light. Perp plays a cell-type-specific role in
p53-mediated apoptosis, being dispensable for apoptosis in
fibroblasts but essential for apoptosis of thymocytes and embryonic
neurons in response to DNA damage signals [47]. To examine
Perp’s role in p53-dependent apoptosis in keratinocytes, 6-week
old K14CreER;Perpfl/fl and control mice were injected with
tamoxifen (which ablated Perp expression in K14CreER;Perpfl/fl
mice; Figure 2A), and 4 weeks later, mice were exposed to one
dose of 2.5 kJ/m2 of UVB radiation. We confirmed that p53 is
induced 24 hours after UVB treatment in the epidermis of both
wild-type and K14CreER;Perpfl/fl mice (Figure 2B). Apoptotic
indices were then determined by quantifying the number of
cleaved Caspase 3-positive cells in the epidermis. Minimal
apoptosis was detected in untreated skin of mice of all genotypes
(Figure 2C, 2D). While robust apoptosis was observed in the
epidermis of wild-type mice in response to UVB radiation, p53 null
mice displayed significantly attenuated levels of apoptosis
(Figure 2C, 2D). Interestingly, analysis of the epidermis of Perp-
deficient mice also revealed diminished apoptosis levels, to an
extent nearly equivalent to p53 loss (Figure 2C, 2D). We confirmed
these findings by assaying apoptosis in differentiated keratinocytes
in vitro, through analysis of both cleaved Caspase 3 positivity and
classical apoptotic nuclear morphology and condensed chromatin
by DAPI staining [48,49]. We found that Perp2/2 keratinocytes
displayed defective apoptosis in response to UVB, similar to
p532/2 keratinocytes (Figure 2E–2G). Together, these results
demonstrate that Perp plays an important role in UVB-induced
apoptosis in both the skin in vivo and keratinocytes in vitro. As p53
inactivation is proposed to promote UVB-induced carcinogenesis
by allowing inappropriate survival of cells sustaining UVB-induced
damage [50], enhanced survival of Perp-deficient cells after
exposure to ultraviolet light could similarly enable tumor
initiation.
Desmosome components, but not adherens junction
components, are selectively downregulated during
tumorigenesis
As a key desmosomal constituent in the epidermis, Perp loss
could also promote cancer through effects on cell-cell adhesion. In
constitutive Perp knockout mice, Perp loss does not abrogate
desmosome formation, but leads to decreased numbers of
desmosomes and reduced stability of desmosomal components
[43]. Simple immunofluorescence analysis of desmosome proteins
in Perp2/2 newborn skin or K14CreER;Perpfl/fl adult mouse skin
does not show perturbed membrane localization of desmosomal
components ([43], Figure 1A, Figure 3A), and thus it is necessary
to use a biochemical assay to show that desmosomes are
functionally compromised upon Perp loss. This solubility assay is
based on the fact that properly formed desmosomal complexes can
only be solubilized by chaotropic agents, whereas improperly
assembled desmosomal components can be solubilized by the
nonionic detergent Triton X-100 [51]. We found that the
desmosomal constituents Desmoglein 1/2 and Plakoglobin
displayed enhanced Triton X-100-solubility in skin from
K14CreER;Perpfl/fl mice compared to skin from control mice
(Figure 3B), confirming that acute deletion of Perp leads to
impaired desmosome function similar to that observed in
constitutive Perp2/2 mice [43].
To determine whether Perp ablation might facilitate tumorigen-
esis by promoting complete desmosome loss, tumors from Perp-
deficient mice were analyzed for the expression of Desmoglein 1/3
and Plakoglobin. Both the percentage of epithelial cells expressing
each marker at the plasma membrane and the intensity of staining
were measured. Staining for each antigen in tumors was
categorized as high (.70%), medium (30–70%), or low (,30%)
level expression. Analysis of the tumors in the K14CreER;Perpfl/fl
mice revealed that the majority of lesions expressed low levels of
desmosome components, suggesting that desmosome dissolution
had occurred (Figure 3C, 3D). Thus, complete desmosome
destabilization can occur during tumorigenesis.
To assess whether this loss of desmosomal component
expression reflected a general change in differentiation status of
the cells during tumorigenesis, such as Epithelial to Mesenchymal
Transition (EMT) [52], we stained tumors for markers of adherens
junctions. Interestingly, most cells in the tumors displayed robust
membrane staining for both E-cadherin and Beta-catenin,
suggesting that adherens junctions remained intact (Figure 3C,
3D). The observation that adherens junctions are maintained
suggests that desmosome loss does not promote tumorigenesis
through a general trans-differentiation mechanism, but rather
through a more specific mechanism related to changes caused by
complete desmosome-deficiency. Accordingly, staining of tumors
arising in the Perp-deficient mice for Smooth Muscle Actin and
Keratin 8 revealed a lack of expression of these markers (data not
shown). Together, these data indicate that Perp loss can facilitate
desmosome downregulation and that direct loss of desmosomes
contributes to tumor development, but in a manner distinct from
that of adherens junction dysfunction.
We also sought to establish whether desmosome destabilization
occurred during SCC development in control animals by staining
tumors from these mice for desmosomal proteins. Whereas non-
lesional skin in the control mice exhibited normal expression of
Perp, Desmoglein 1/3, and Plakoglobin (data not shown), all of the
tumors from these mice displayed low level expression of one or
more desmosomal components (Figure 3E). Interestingly, in this
case, Desmoglein 1/3 appeared to be lost most commonly. Since
desmosomes were intact at the beginning of the study, these data
Punctate desmosomal pattern in the epidermis is comparable to that observed in wild-type mouse keratinocyte monolayers. B) Tumor study design.
C) Kaplan-Meier analysis showing tumor latency in UVB-treated control (Perpfl/fl and Perpfl/+) and K14CreER;Perpfl/fl mice. Statistical significance was
determined using the Log Rank test (* p = 0.0002). n = 25 for each genotype. D) (Left) Graph depicts the average number of SCCs per UVB-treated
mouse +/2 STDEV. Statistical analysis was performed using the Student’s unpaired t-test (* p = 0.00049). (Right) Representative photographs of
tumor burden in control and K14CreER;Perpfl/fl mice, with arrow indicating a tumor. E) Representative Hematoxylin and Eosin (H&E) stained images
illustrating the various SCC grades. F) Table indicating the numbers of SCCs of different grades in UVB-treated control and K14CreER;Perpfl/fl mice.
doi:10.1371/journal.pgen.1001168.g001
Perp and Skin Cancer
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further suggest that targeted downregulation of the desmosome is
an active characteristic of tumor development, and that weakened
desmosomal adhesion, as in the case of Perp-deficiency, facilitates
this downmodulation. In addition, analysis of adherens junction
components in control tumors revealed intact E-cadherin and
Beta-catenin expression at the plasma membrane, similar to
tumors in the K14CreER;Perpfl/fl mice (Figure 3E). Thus, down-
regulation of desmosomal constituents with maintenance of
adherens junctions is a general feature of SCC development.
Perp expression is downregulated in human SCCs
Our findings suggest that desmosome loss, coupled with
maintenance of adherens junctions, may represent an important
stage of tumorigenesis. To determine the relevance of this
observation to human SCC development, we stained a panel of
samples reflecting different stages of human skin SCC develop-
ment, ranging from actinic keratoses to moderately differentiated
SCCs, for both PERP and E-cadherin. Each sample was scored
based on the percentage of epithelial cells exhibiting membrane
staining in addition to the intensity of the membrane staining in
the epithelial portion of each tumor. Samples with greater than
10% of the epithelial cells expressing intense membrane staining
were given a positive score, while those with less than 10% of the
epithelial cells expressing either PERP or E-cadherin were given a
negative score. We first noted a significant decline in the
percentage of samples displaying Perp expression in the transition
between AKs and SCCIS, suggesting that Perp expression is
downregulated during tumor progression (p= 0.049, z-test).
Interestingly, while a subset of all tumors displayed intact PERP
and E-cadherin expression and another group showed complete
lack of expression of both PERP and E-cadherin, the majority of
tumors (57%) lacked PERP expression while retaining E-cadherin
expression, akin to our observations in the mouse SCC model
(Figure 4A, 4B). These findings suggest that PERP loss with
retention of E-cadherin represents a significant phase of human
tumorigenesis. Moreover, since the vast majority of all SCCs
examined (93%) retain E-cadherin expression, and since E-
cadherin loss is thought to be a late event in tumorigenesis, our
data suggest a temporal sequence whereby PERP loss occurs
before E-cadherin loss in the progression of human SCC.
Perp ablation induces an inflammatory gene signature
To understand how Perp-deficiency might cooperate with
chronic UVB exposure to promote cancer, we performed
microarray analyses to identify those genes whose expression is
altered upon Perp loss. Cohorts of K14CreER;Perpfl/fl and control
mice were generated and skin was processed for RNA analysis two
weeks post tamoxifen injection, a timepoint at which we could first
detect Perp protein expression loss throughout the epidermis
(Figure 5A). Using Significance Analysis of Microarrays (SAM)
[53], we identified a panel of 143 genes that were differentially
regulated in the K14CreER;Perpfl/fl mice compared to controls
(FDR=10%; Figure 5B). These included 51 upregulated and 92
downregulated genes. We next classified the genes changing with
altered Perp status based on Gene Ontology functional annotation.
The three largest statistically significantly enriched groups of genes
upregulated upon Perp ablation were in the categories of metabolic
process, transport, and immune system process (Figure 5C).
Significantly enriched classes of genes downregulated upon Perp
loss included those linked to developmental processes and cell
communication (Figure 5C). To identify genes whose induction
might promote cancer, we examined those genes that were most
highly upregulated in the absence of Perp. Interestingly, upon
examination of the list of genes induced 3-fold or greater in the
absence of Perp, we discovered that the most highly induced were
several inflammation-related genes (Figure 5D). These included:
Interleukin 1 Family member 6 (Il1f6), an inflammatory cytokine
sufficient to induce an inflammatory response when expressed in
keratinocytes of transgenic mice [54]; S100a9, a calcium binding
protein with cytokine-like function in inflammation and cancer
[55,56]; Chitinase 3-like 1 (Chi3l1), a mammalian chitinase
involved in enhancing inflammation as well as angiogenesis and
extracellular matrix remodeling, thereby promoting tumorigenesis
[57]; and Chemokine ligand 20 (Ccl20), an established chemoat-
tractant for subsets of lymphocytes and dendritic cells which is also
known to promote tumor growth [58–61]. Additionally, this list
included Il22ra, a class II cytokine receptor and mediator of innate
immune responses [62]. Quantitative RT-PCR analysis verified
that the expression of these genes is indeed significantly induced in
the skin of Perp-deficient mice (Figure 5E, data not shown).
Chronic UVB exposure combined with Perp loss leads to
the recruitment of immune cells to the skin
The induced inflammatory gene signature in Perp-deficient
mice could reflect gene expression changes intrinsic to keratino-
cytes, or, alternatively, the recruitment of inflammatory cells to the
skin of Perp-deficient mice. To distinguish these possibilities, we
analyzed untreated K14CreER;Perpfl/fl and control skin samples for
the presence of inflammatory cells. Histological staining for T-
cells, mast cells, and myeloid cells indicated no difference in
immune cell numbers between the Perp-ablated samples and the
controls (Figure 5F–5I, data not shown), suggesting that Perp-
deficiency induces an inflammatory gene expression program
directly in keratinocytes rather than causing recruitment of
immune cells to the skin.
The observation that Perp loss triggers the induction of genes
known to promote inflammation, combined with the fact that
inflammation is causally linked to cancer development [63],
Figure 2. Perp loss compromises UVB-induced apoptosis in vivo and in vitro. A) Perp immunohistochemistry showing loss of Perp in the
epidermis of tamoxifen-treated K14CreER;Perpfl/fl mice. Dashed line demarcates epidermis (EP) and dermis (D). B) Immunohistochemistry showing p53
stabilization (arrows) in the epidermis of both control and K14CreER;Perpfl/flmice 24 hrs after treatment with 2.5 kJ/m2 UVB radiation. C) Cleaved Caspase 3
(CC3) immunohistochemistry to detect apoptosis in the epidermis of untreated and UVB-treated mice of different genotypes. Arrows indicate apoptotic
cells. D) Quantification of apoptosis in untreated and UVB-treated control, K14CreER;Perpfl/fl, and p532/2 mice. Graph depicts the average number of
cleaved Caspase 3 (CC3)- positive cells per linear cm of epidermis, +/2 SEM. Data were derived from the analysis of segments of skin at least 2–3 cm long
per mouse, in several independent experiments with the following numbers of mice: wild-type controls (n= 8), K14CreER;Perpfl/fl (n= 12), p532/2 (n= 5).
Statistical analysis was conducted using the Student’s unpaired t-test (* p= 0.0017 versus treated wild-type and ** p=0.0003 versus treated wild-type). (E)
Representative immunofluorescence images of wild-type, Perp2/2, and p532/2 keratinocyte monolayers, either untreated or treated with 1 kJ/m2 UVB,
and stained with a cleaved Caspase 3 antibody and DAPI to measure apoptosis. (F) Higher magnification images show apoptotic cells, which display both
cleaved Caspase 3-positivity and nuclear blebbing and chromatin condensation by DAPI staining, hallmarks of apoptosis (G) Quantitation of the
percentage of apoptotic cells per 2006 field in untreated and UVB-treated wild-type, Perp2/2, and p532/2 keratinocytes, as assessed by cleaved
Caspase 3/DAPI staining. Graph represents the average +/2 SEM of three independent experiments performed in triplicate. Statistical analysis was
conducted using the Student’s unpaired t-test. (* p= 0.011 versus treated wild-type and ** p=0.0029 versus treated wild-type).
doi:10.1371/journal.pgen.1001168.g002
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Figure 3. Adhesion junction analysis in tumors from K14CreER;Perpfl/fl and control mice. A) Representative Hematoxylin and Eosin (H&E)
staining and immunofluorescence images of desmosome and adherens junction component protein expression in skin from tamoxifen-treated
K14CreER;Perpfl/fl mice demonstrating that Perp loss itself does not disrupt membrane expression of other adhesion proteins. B) Western blot analysis
showing both the Triton X-100-soluble and urea-only soluble fractions of mouse epidermal lysates from control and K14CreER;Perpfl/fl mice.
Desmoglein 1/2 (Dsg 1/2) and Plakoglobin (Pg) solubility were examined. Gapdh serves as a loading control for the Triton X-100-soluble pool, while
Keratin 14 serves as the loading control for the urea fraction. C, D) Tumors from K14CreER;Perpfl/fl mice were stained with antibodies against various
desmosomal and adherens junction components, and both the percentage of epithelial cells staining positive for each marker and the intensity
of staining were measured. Staining for each antigen was categorized as high (.70%), medium (30–70%), or low (,30%) level expression.
C) Representative H&E and immunofluorescence images of a K14CreER;Perpfl/fl tumor sample demonstrating desmosomal component loss with
retention of adherens junction components. Green signal indicates antigen staining, and blue signal indicates DAPI-marked nuclei. D) (Left) Graph
showing the percentages of K14CreER;Perpfl/fl tumors categorized into respective groups based on quantitative immunofluorescence staining for
Plakoglobin and Desmoglein 1/3. (Right) Graph depicting the percentages of tumors categorized into respective groups based on
immunofluorescence staining for E-cadherin and Beta-catenin. (E) Tumors from control wild-type mice were stained for desmosomal and adherens
junction components, and each component was categorized as displaying high, medium, or low level expression, as described above. (Left) Graph
showing the percentages of control tumors categorized into respective groups based on quantitative immunofluorescence staining for Perp,
Plakoglobin, and Desmoglein 1/3. (Right) Graph depicting the percentages of tumors categorized into respective groups based on
immunofluorescence staining for E-cadherin and Beta-catenin.
doi:10.1371/journal.pgen.1001168.g003
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provides a rationale for how Perp-deficiency could contribute to
cancer. We hypothesized that persistent cytokine/chemokine
signaling in K14CreER;Perpfl/fl mice, combined with chronic UVB
exposure, might ultimately attract immune cells, thereby promot-
ing tumor formation. To investigate this idea, we queried the
presence of inflammatory cells in the skin from a subset of control
and K14CreER;Perpfl/fl mice at an intermediate timepoint in the
tumor study, after 19 weeks of chronic UVB treatment, by
quantifying numbers of myeloid cells, T-cells, and mast cells
(Figure 6A–6F). While we did not detect any differences in the
number of myeloid cells, assessed by MPO-positivity (Figure 6A,
6B; [64]), we did observe increased numbers of T-cells present
throughout the skin of K14CreER;Perpfl/fl mice compared to
controls (Figure 6C, 6D). Moreover, we noted a striking increase
in mast cell numbers in the skin from K14CreER;Perpfl/fl mice
relative to controls (Figure 6E, 6F). As mast cells have been
reported to surround tumors in a variety of cancers, including
SCCs [65–68], and because they have been shown to play a key
role in promoting tumorigenesis through the secretion of factors
that remodel the tumor microenvironment and stimulate angio-
genesis [68–71], their presence in the UVB-treated Perp-deficient
mouse skin suggests an additional mechanism through which Perp
loss may stimulate tumorigenesis.
Discussion
The importance of disrupted cell-cell adhesion for cancer
development is underscored by the observed downregulation of
adherens junction components during human cancer progression
and genetic experiments demonstrating tumor prone phenotypes
Figure 4. PERP loss with E-cadherin maintenance is a common event in human skin SCCs. A) Representative PERP and E-cadherin
immunostaining of SCCs illustrating different expression patterns at low (left 100:1) and high (right 400:1) power magnification. Examples of PERP+;E-
cadherin+ (i), PERP2;E-cadherin2 (ii), and PERP2;E- cadherin+ (iii) tumors are shown. Dashed boxes indicate regions shown in the high magnification
images. B) Table quantifying the numbers and percentages of SCCs with specific staining patterns for PERP and E- cadherin expression. Note the high
percentage of tumors exhibiting strong E-cadherin staining, but no PERP staining.
doi:10.1371/journal.pgen.1001168.g004
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of mice deficient for E-cadherin, Alpha-catenin, or p120-catenin,
components of the adherens junction [19–21]. In contrast, the
data regarding desmosome protein expression during human
cancer progression are conflicting [35–41], and the contribution of
desmosome dysfunction to cancer development has not been
clearly established using in vivo mouse models. Here, we show that
loss of the desmosomal component Perp predisposes mice to UVB-
induced SCC development by enhancing both tumor initiation
and progression. The effects of Perp ablation are at multiple levels,
leading both to compromised apoptosis in response to ultraviolet
light and loss of desmosomal adhesion (Figure 7). The defective
apoptosis could allow the inappropriate survival of damaged cells,
which could help initiate tumors. The exact mechanism through
which Perp promotes apoptosis remains to be elucidated, but it
may relate to Perp function at the desmosome, as apoptotic defects
were previously reported in cells lacking either the desmosomal
component desmoglein 1 or desmoglein 2 [72,73]. In addition,
compromised UVB-induced apoptosis in the epidermis has also
been observed in mice lacking the p53 target gene Noxa, a member
of the Bcl-2 family [74]. Our findings indicate that Noxa is
insufficient to drive apoptosis in the absence of Perp, and therefore
that Perp and Noxa may collaborate to cause apoptosis. In
addition, we observe perturbations in desmosomal adhesion.
Interestingly, the desmosome downregulation we observe in
tumors occurs without adherens junction loss or other signs of
EMT, highlighting a specific role for desmosome loss in tumor
development. It may be that desmosome loss occurs during early
stages of tumorigenesis, facilitating early cancer progression, and
that adherens junctions are lost subsequently, thereby promoting
invasion and metastasis phenotypes. Our analysis of human SCC
samples supports the idea that PERP-deficient, E-cadherin positive
samples reflect an important stage of human skin carcinogenesis.
To understand further how Perp-deficiency might enhance
tumor development, we examined gene expression profiles upon
Perp loss. Interestingly, several of the genes induced upon Perp
inactivation are known to be involved in promoting inflammation
and tumorigenesis [54–62]. Inflammation is a well-established
causative factor in tumorigenesis [63], as evidenced by tumor-
prone mouse strains deficient for specific subsets of immune or
inflammatory cells exhibiting reduced tumor burdens [66,75]. The
induction of a set of inflammation-associated genes presents a
plausible explanation for how Perp-deficiency can promote cancer
in cooperation with chronic UVB damage. Indeed, we found that
Perp-deficiency, in conjunction with chronic UVB exposure, led to
the infiltration of T-cells and mast cells. Mast cells can clearly
promote tumorigenesis [69–71], and their accumulation in the
UVB-treated, Perp-deficient epidermis provides another mecha-
nism through which Perp loss can stimulate cancer development
(Figure 7).
Some of the previous controversy about whether desmosomal
components promote or inhibit cancer may relate to differences in
the contribution of desmosomes in different contexts. Depending on
the tissue type, the genetic lesions already accrued, and the tissue
microenvironment, desmosome-deficiency may have different
effects. Indeed, certain proteins, such as Tgf-ß1 and E2f1, can
have either pro- or anti-tumorigenic roles depending on the exact
setting [76,77]. Consistent with this notion, skin carcinogenesis
experiments in which Perp-deficient mice were treated with DMBA/
TPA showed that Perp loss actually hindered the development of
papillomas, suggesting that Perp enables the formation of this type
of tumor [78]. Importantly, however, loss of the p53 tumor
suppressor in this model also reduces papilloma formation,
suggesting that this may represent an atypical route to tumorigenesis
[79]. Therefore, in the study described here, we sought to analyze
Perp function in an accurate model for human cancer, by treating
mice with UVB, the causative factor for SCC of the skin.
Our studies also provide insight into mechanisms of p53-
mediated tumor suppression in skin cancer. The relevance of
p53 in skin cancer development is highlighted by the observa-
tions that p53 is mutated in at least 90% of human SCCs [80]
and that p53 null mice display an enhanced predisposition to
UVB-triggered skin cancer [44,81]. While p53’s ability to drive
apoptosis in response to ultraviolet light has been shown to limit
SCC formation [82], the molecular pathways underlying p53’s
tumor suppressor properties are incompletely understood. p53 is
a transcriptional activator, but the genes mediating p53 tumor
suppressor function have been unclear, as none of the mouse
strains deficient for p53 target genes exhibits a spontaneous
tumor predisposition [83]. Instead, analysis of target genes in
specific contexts may reveal key functions as mediators of p53
tumor suppressor function. This notion is exemplified by studies
of the apoptotic target gene Puma, which is important for p53
tumor suppression in the setting of Em-myc driven B-cell
lymphomas [84]. Our studies have provided important novel
insight into pathways of p53 tumor suppression by suggesting
that Perp is a critical mediator of p53 tumor suppressor function
in UVB-induced SCC development. In addition, although the
role of p63 in cancer has been more controversial, Perp loss
could also potentially explain how tumors might arise in the
absence of p63.
Figure 5. Perp-deficiency induces expression of inflammation-related genes. A) Perp immunofluorescence demonstrating Perp loss in the
epidermis of K14CreER;Perpfl/fl mice two weeks after tamoxifen injection. B) Genes differentially expressed between control K14CreER;wild-type and
K14CreER;Perpfl/fl skin were identified using SAM (Significance Analysis of Microarrays) with an FDR of 10%. The 143 genes (51 induced and 92
repressed in Perp-deficient skin compared to control skin) are grouped by hierarchical clustering and represented in the heat map. C) Major classes of
genes upregulated and downregulated in K14CreER;Perpfl/fl skin compared to controls, as determined by Gene Ontology (GO) annotation. Members of
the metabolic process, transport, immune system process, developmental process, and cell communication categories were statistically significantly
enriched (p = 6.7361024, p = 3.5261023, p = 8.9161023; p = 1.5961022, p = 2.4761022, respectively, by the binomial statistic). D) Table of genes
induced 3 fold or greater in K14CreER;Perpfl/fl skin relative to control samples. E) Quantitative-RT-PCR analysis validating Il1f6 (* p = 3.161025), s100a9
(* p = 0.00022), Chi3l1 (* p = 1.261026), and Ccl20 (* p = 0.0002) as genes induced upon Perp loss. Graphs represent the average expression levels in
the skin of five mice examined in triplicate +/2 SEM. Statistical significance was calculated using the Student’s unpaired t-test. F) Representative
immunofluorescence images of CD3-positive T-cells in control versus K14CreER;Perpfl/fl mouse skin. T-cells are stained in green (arrows) and nuclei are
stained with DAPI in blue. EP indicates epidermis and D indicates dermis, with white dashed line delineating the boundary between the two
compartments. G) Quantification of CD3-positive T-cells in the skin of control and K14CreER;Perpfl/fl mice. Graph represents the average number of
CD3-positive T-cells counted in triplicate 2006fields, from the skin of each of at least 5 mice, +/2 SEM. Statistical significance was analyzed using the
Student’s unpaired t-test. (p = 0.21). H) Representative images of staining for toluidine blue-positive mast cells in control and K14CreER;Perpfl/fl mouse
skin. Dashed box represents area seen in higher magnification (400:1) images below. Note that mast cells are identified by the purple stain (arrows),
which differs from the blue stained background due to pH differences within mast cells. I) Quantification of mast cell numbers in the skin of control
and K14CreER;Perpfl/fl mice. Graph represents the average number of mast cells counted in triplicate 2006 fields, from the skin of each of 5 mice, +/2
SEM. (p = 0.7; Student’s unpaired t-test).
doi:10.1371/journal.pgen.1001168.g005
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Figure 6. Combined Perp-deficiency and chronic UVB exposure induce immune cell infiltration in the skin. A) Representative
immunofluorescence images of myeloid cells, as determined by MPO staining (arrows), in the skin of control and K14CreER;Perpfl/fl mice treated with
UVB light for 19 weeks. B) Quantification of MPO-positive cells in UVB-treated cohorts. Graph represents the average of 3 mice, quantified in triplicate
2006 fields +/2 SEM. (p = 0.89; Student’s unpaired t-test). C) Representative immunofluorescence images of T-cells, as assessed by CD3 staining
(arrows), in the skin of control and K14CreER;Perpfl/fl mice treated with UVB light for 19 weeks. D) Quantification of CD3-positive T-cell numbers in
UVB-treated cohorts. Graph represents the average number of T-cells in the skin of 3 mice, quantified in triplicate 2006 fields, +/2 SEM. (* p = 0.044,
Student’s unpaired t-test). E) Representative images of staining for mast cells, as assessed by toluidine blue-positivity (arrows), in the skin of control
and K14CreER;Perpfl/fl mice treated with UVB light for 19 weeks. Note the increase in mast cells underlying the epidermis in the K14CreER;Perpfl/fl mice.
F) Quantification of mast cells in UVB-treated cohorts. Graph represents the average of 3 mice, quantified in triplicate 2006 fields +/2 SEM. (* p =
0.0092; Student’s unpaired t-test).
doi:10.1371/journal.pgen.1001168.g006
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Figure 7. Model for how Perp-deficiency can promote tumorigenesis. Perp loss, combined with chronic UVB exposure, can promote cancer
through three mechanisms. A) Compromised apoptosis in the epidermis of Perp-deficient mice in response to UVB light can lead to inappropriate
survival of cells sustaining DNA damage and expansion of pre-malignant cells. B) Impaired desmosomal adhesion in Perp-deficient mice, depicted by
downregulation of a desmosomal cadherin, can facilitate the complete disruption of desmosomes that stimulates tumorigenesis. The exact
placement of Perp, a tetraspan membrane protein, within the desmosome is speculative. C) The recruitment of inflammatory cells to the skin of UVB-
treated Perp-deficient mice can promote cancer through mechanisms such as enhancing remodeling of the tumor microenvironment or stimulating
angiogenesis.
doi:10.1371/journal.pgen.1001168.g007
Perp and Skin Cancer
PLoS Genetics | www.plosgenetics.org 12 October 2010 | Volume 6 | Issue 10 | e1001168
Non-melanoma skin cancer is one of the most common
malignancies in the US [85]. Fortunately, identifying SCC lesions
before they progress into poorly differentiated tumors is aided both
by facile detection and increased awareness of the consequences of
chronic sun exposure. However, this is not the case for other
stratified epithelia-derived cancers such as head and neck or
esophageal cancers, which have poor survival rates [86]. Our
findings may provide a framework to better understand how these
more deadly diseases progress. Indeed, the loss of desmosomal
component expression with maintenance of adherens junction
expression observed in the K14CreER;Perpfl/fl mouse tumors and in
human skin SCCs was recapitulated in samples derived from
humans with head and neck SCCs (data not shown). The idea that
desmosome loss may precede adherens junction loss could have
important clinical implications. While E-cadherin status can
provide a useful prognostic indicator for a variety of epithelial
cancers, loss of this marker is associated with late-stage tumor
progression [16,87,88]. Identifying markers like PERP that are
altered earlier during tumorigenesis could potentially enhance
diagnosis, grading, and prognostication, leading to more informed
choices of therapy. The increased frequency of advanced tumors
in the Perp-deficient mice relative to controls supports the idea
that human tumors lacking PERP may ultimately progress more
aggressively, and thus that PERP status may provide a useful
diagnostic or prognostic marker. Indeed, previously published
expression profiling studies suggest that PERP may be one in a
group of key predictors for patient treatment response in
esophageal cancers [89]. Further investigation of the potential
diagnostic and prognostic value of PERP expression in human
cancers represents an exciting avenue to pursue.
Materials and Methods
Ethics statement
All animal studies were approved by the Stanford University
Administrative Panel on Laboratory Animal Care and were
performed in strict accordance with IACUC guidelines.
Tumor study
Keratin-14CreERT2 mice were bred to Perpfl/fl conditional mice
and kept on a 129/Sv; C57BL/6 mixed background [46]. At 6
weeks of age, 0.1 mg of tamoxifen (Sigma Chemical Corp., St.
Louis, MO) diluted first in ethanol then in corn oil was
administered to mice for 5 consecutive days via intraperitoneal
injection. Four weeks post-injection, mice began chronic UVB
treatments (2.5 kJ/m2, three times a week, for 30 weeks). Mice
were shaved on a weekly basis and treated using Kodacel-filtered
FS40 sunlamps. Mice were placed 5 in a cage and allowed to roam
freely during treatment. Cages were rotated along the shelf below
the light bulbs before each treatment to compensate for uneven
distribution of energy along the bulbs. Mice were monitored for
tumor incidence by visual inspection.
Immunofluorescence/immunohistochemistry
Tissue samples were fixed overnight in 10% formalin,
processed, and embedded using standard procedures. Samples
were deparaffinized, rehydrated, and unmasked using Trilogy
(Cell Marque, Rocklin, CA) in a pressure cooker for 15 minutes
according to the manufacturer’s instructions. Samples were then
rinsed in phosphate buffered saline (PBS) and blocked in PBS
containing 5% normal goat serum (Sigma Chemical Corp.), 2.5%
bovine serum albumin (Sigma Chemical Corp.), and 0.01% Triton
X-100 (Fisher Scientific, Pittsburgh, PA). Sections were incubated
in primary antibody overnight at 4uC, rinsed in PBS with 0.01%
Tween-20 (Fisher Scientific), incubated with secondary antibody
and 1 mg/mL 49,6-diamidino-2-phenylindole (DAPI) (Sigma
Chemical Corp.) for 1 hr at 37uC, and washed in PBS. Samples
were mounted with Mowiol (EMD Chemicab, Gibbstown, NJ).
Fluorescence images were examined using a Leica DM6000B
microscope (Leica Microsystems, Bannockburn, IL), and images
were acquired using a Retiga Exi Camera (Q imaging, Surrey,
British Columbia, Canada) and Image Pro 6.2 software from
Media Cybernetics (Silver Spring, MD).
Keratinocyte culture and apoptosis assays
Keratinocytes were derived from P.05–P1.5 mouse skin as
described [43]. Cells were grown on collagen/fibronectin-coated
dishes and maintained in an undifferentiated state by growing the
cells in low calcium EMEM (Lonza, Basel, Switzerland) containing
0.05 mM calcium, 8% dialyzed FCS, and antibiotics. Cells were
then differentiated for 24 hrs in the same media as the
undifferentiated cells, except the calcium concentration was raised
to 2 mM. For immunofluorescence, keratinocytes were grown on
collagen/fibronectin-coated glass coverslips. For UVB treatment,
media was removed and cells were washed once in PBS, then
treated with 1 kJ/m2 UVB radiation using a Kodacel filter
(Eastman Kodak, Rochester, NY) to block residual UVC rays.
After 48 hours, cells were fixed in cold methanol for 20 minutes
at 220uC. Cells were stained with rabbit anti-cleaved Caspase 3
antibodies (Cell Signaling, Beverly, MA), followed by staining with
FITC-anti-rabbit antibodies (Vector Laboratories, Burlingame,
CA) and DAPI and mounting using Mowiol.
In vivo apoptosis assays
Cohorts of K14CreER;Perpfl/fl mice were generated, and at 6
weeks of age mice were injected with tamoxifen as described
above. Four weeks later the dorsal skin of mice was shaved. Mice
were placed underneath a Kodacel filter and allowed to roam
freely in their cage during UVB treatment. Half of the dorsal skin
was exposed to a one time dose of 2.5 kJ/m2 of UVB irradiation
while the other half was blocked. 24 hours later the dorsal skin of
the mice was collected and immunostained for cleaved Caspase 3.
Apoptosis, indicated by cleaved Caspase 3-positivity, was quanti-
fied in at least 2–3 cm of skin per mouse.
Antibodies
Primary antibodies against Perp [43], Desmoglein 1 (Santa Cruz
Biotechnology, Santa Cruz, CA), Plakoglobin (clone 11E4; Invitro-
gen), Keratin 14 (Covance, Princeton, NJ), Alpha-tubulin (Sigma
Chemical Corp.), E-cadherin (Invitrogen), GAPDH (Fitzgerald
Industries, Acton, MA), Plakoglobin (1408; gift of K. Green),
Smooth Muscle Actin (Santa Cruz Biotechnology), Desmoglein 1/3
(clone 32-2B; gift of D. Garrod), Desmoglein 1/2 (4B2; gift of K.
Green), cleaved Caspase 3 (Cell Signaling), p53 (Vector Laborato-
ries), Beta-catenin (BD Biosciences, San Jose, CA), Desmoplakin
(11-5F; gift of D. Garrod), CD3 (Dako, Denmark), and MPO
(AbCam, Cambridge, MA) were used in this study. Secondary
antibodies used were: FITC-anti-mouse and FITC-anti-rabbit
(Vector Laboratories) and TRITC-anti-chicken, HRP-anti-mouse,
and HRP-anti-rabbit (Jackson ImmunoResearch, West Grove, PA).
Solubility assays
For the solubility assay, skin samples were frozen and ground
up, resuspended in a 0.1% Triton X-100-based solution, and
nutated for 1 hr at 4uC [43]. The insoluble pellet was lysed in 9M
urea buffer. Samples were then analyzed using conventional
western blotting protocols.
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Human tissue microarrays
Archival paraffin embedded tissue blocks were retrieved from
the Dermatopathology Section of the Department of Pathology
and Dermatology, University of California, San Francisco and
from outside pathology laboratories. Tumor-bearing regions from
paraffin-embedded, formalin-fixed tissue samples were identified
by a dermatopathologist using routine hematoxylin and eosin
stained sections. Tissue microarrays comprising 0.6 mm cores of
skin actinic keratoses, skin carcinomas in situ, skin SCCs, and
adjacent normal tissue samples were constructed. Sections (5 mm)
were cut and placed onto Superfrost plus slides (Fisher Scientific)
[90]. 23 AKs, 20 SCCIS, and 160 SCCs were analyzed.
Microarray analysis
RNA was isolated from the dorsal skin of control and
K14CreER;Perpfl/fl mice two weeks post-tamoxifen injection using
Trizol (Invitrogen), according to the manufacturer’s protocol.
RNA samples were processed at the Stanford University Pan
Facility and analyzed using Affymetrix Mouse Genome 430 2.0
expression arrays. Probe-level data were processed using BRB-
ArrayTools (Biometric Research Branch of the National Cancer
Institute) based on RMA (Robust Multichip Average) for
background adjustment, normalization and expression summari-
zation. Class comparison analysis was conducted using SAM
(Significance Analysis of Microarrays) with an FDR (False
Discovery Rate) of 10% [53]. Gene function categorization based
on GO (Gene Ontology) was carried out using the PANTHER
(Protein ANalysis THrough Evolutionary Relationships) classifi-
cation system.
Quantitative reverse transcription PCR
Skin from control and K14CreER;Perpfl/fl mice was isolated two
weeks after tamoxifen injections. RNA was isolated using Trizol
(Invitrogen), and 1 mg RNA was reverse transcribed using
Moloney Murine Leukemia Virus reverse transcriptase (Invitro-
gen) and random primers. PCR was performed in triplicate using
SYBR green (SA-Biosciences, Frederick, MA) and a 7900HT Fast
Real-Time PCR machine (Applied Biosystems, Foster City, CA),
and results were computed relative to a standard curve made with
cDNA pooled from all samples. Values were first normalized to b-
actin and then represented relative to untreated wild-type samples.
Five mice per genotype were analyzed. Primers used were as
follows: b-actin 59-TCC TAG CAC CAT GAA GAT CAA GAT
C-39, Rev 59-CTG CTT GCT GAT CCA CAT CTG-39, S100a9
59-GGA AGG AAG GAC ACC CTG AC-39, Rev 59-CCA GGT
CCT CCA TGA TGT C-39, Il1f6 59-CTG TTC TGC ACA
AAG GAT GG-39, Rev 59-GCT GCA GAC TCA AAT GTA
GAG G-39, Il22ra 59-GGA CAC CCC GCT TCA CTC-39, Rev
59-ATT TGG CAA CTC TGG AGG AC-39, Chi3l1 59-AGC
AGT ATT TCT CCA CCC TGA T-39, Rev 59-CGC TGA GCA
GGA GTT TCT CT-39, and Ccl20 59-AAC TGG GTG AAA
AGG GCT GT-39, Rev 59-GTC CAA TTC CAT CCC AAA
AA-39.
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